The QuEChERS Approach to Determine Pharmaceuticals and ...
Transcript of The QuEChERS Approach to Determine Pharmaceuticals and ...
The QuEChERS Approach to Determine Pharmaceuticals and Toxins in Whole
Blood
Joan Stevens, Ph.D., Chemistries and Supplies Division, Agilent Technologies, Inc.
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
IntroductionBlood is the most complex of the biological fluids
Determination of drugs in whole blood is often necessary in forensic analysis because of the difficulty in obtaining serum or plasma
Conventional procedures to analyze drugs in complex matrices like whole blood involve tedious, time consuming, expensive, and complex steps, and possible sample loss and contamination problems are not unusual
QuEChERS is a sample preparation technique that was developed for the extraction of multi-class pesticide residue from fruits and vegetables, in 2003
Although biological fluids may seem vastly different than a piece of fruit they follow parallel paths
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Comparison
Biological Fluids
Complex matrices
Disrupt cell architecture – Lyses, vortexing. organic
solvent, hydrolysisAnalytes with a wide range of polarities
Remove analyte or matrixAnalysis by LC/MS/MS, GC/MS or GC/MS/MS
Fruits and Vegetables
Complex matrices
Disrupt cell architecture– Mincing, vortexing, organic
solvent, hydrolysisAnalytes with a wide range of polarities
Remove analyte or matrixAnalysis by LC/MS/MS, GC/MS or GC/MS/MS
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Basic SPE Procedure for Blood Sample
• Pretreatment of whole blood involves dilution with an acidic solution, phosphate buffer or water/FA
• Sonicate 15 minutes; disrupts cell membranes
• Centrifuge– SPE procedure
• Condition cartridge: methanol, water• Load cartridge: sample
• Wash cartridge: aqueous methanol or buffer % methanol• Elut cartridge: eluent for analysis
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Basic QuEChERS Procedure
15 g homogenized sample, (spike)
Add 15 mL ACN (1% AA), vortex
Add AOAC Extraction Salts, shake
Centrifuge
Transfer 1 or 8 mL to AOAC d-SPE tube, vortex, centrifuge
Transfer to Analysis vial
CN (1
xtrac
entr
OAC
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Advantages of QuEChERS Procedure
• Liquid-liquid type extraction
• Use of acid to interrupt protein binding
• Excess salts to lyses cellular components
• Use of acetonitrile to facilitate protein precipitation
• Use of dispersive SPE to adsorb matrix interferences
3/23/2011
Plossl, et.at., J Chrom A, 1135 (2006), 19-26
•
For Research Use Only. Not for use in diagnostic procedures.
Disadvantages of QuEChERS Procedure
• Sample and solvent amount required in the method, are not “biological friendly”
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Opposing Sample Preparation Ideas
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Compatible Sample Preparation Techniques
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Purpose Behind the mini-Q Approach
• Offer a more biological friendly approach
• Small sample and volume requirements
• Range of drug compounds, various polarities and pKa
• Evaluation of background interferences
• Extraction and recovery data in acceptable range
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
mini-QuEChERS: mini-QProcedure:• Add 2 ceramic homogenizers• 1 or 2 mL whole blood added to a centrifuge tube with screw
cap• Add std soln or IS soln, vortex• Add 2 mL acidified ACN, vortex 30 sec• Add 500 mg of extraction salts, vigorously shake 1 minute,
centrifuge 5000 rpm, 1 min• Transfer 1 mL of extract to d-SPE material in centrifuge tube,
vortex, centrifuge • Add 200 uL to 800 uL water in LC vial, vortex analyze
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Refinement of mini-Q ProcedureParameters evaluated in the mini-Q technique
• Whole blood sample– Most complicated biological matrix
• Addition of acid, type and amount– Effect on partitioning and extraction
• Addition of QuEChERS salts, non-buffered, NaAcetate, or Citrate buffered– Effect on extract, visual inspection
• Dispersive SPE– Matrix cleanup and compound recoveries
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Addition of Acid to Acetonitrile extraction solvent
• Use of acetic acid versus formic acid – Evaluation of a series of acidic acetonitrile solutions in which the percentage
of acid was increased
ACN 1% AA/ACN ACN
Clumping and sticky results
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
• Addition of 0.4% formic acid/acetonitrile
EN: citrate buffers AOAC: NaAcetate Non-buffered: NaCl
Lyses of cellular structure, increased particulate nature
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
• Evaluation of QuEChERs salts: Partitioning/Extraction– EN: NaCl, Sodium citrate buffers, Mg SO4– AOAC: NaAcetate and MgSO4
– Nonbuffered: NaCl and MgSO4
EN: Citrate salts AOAC: NaAcetate Non-buffered: NaCl
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
• Dispersive SPE– Remove matrix interferences: PSA*, C18, GCB, MgSO4– D-SPE: PSA and MgSO4
*PSA: Primary and secondary amine
d-SPE EN: Citrate AOAC: NaAcetate Non-buffered: NaCl EN d-SPE AOAC: d-SPE AOAC: d-SPE AOAC: d-SPE
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Pharmaceuticals Used in StudyCompound CAS number Log P (o/w) pKa Therapeutic Use
Lidocaine 137-58-6 2.4 8.01 Local anesthetic,antiarrhythmic
Tramadol 27203-92-5 2.5 9.41 Analgesic
Amitriptyline 50-48-6 4.92 9.4 Antidepressant
Biperidene 514-65-8 4.0 10.8 Anticholinergic
Oxazepam 604-75-1 2.23 1.7, 11.3 Antianxiety
Lorazepam 846-49-1 2.47 1.3, 11.5 Antidepressant
Chlorpromazine 50-53-3 5.18 9.3 Antipsychotic
Diltiazem 42399-41-7 3.63 7.7 Calcium channel blocker
Naloxone 465-65-6 1.45 7.9 Opioid Receptor Antagonist
Nortriptyline (IS) 72-69-5 5.65 9.7
5 ug/mL stock solution (9 compounds) and IS in methanol
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
LC/MS/MS Acquisition DataCompound MRM channels (m/z) Fragmentor (V) CE (V) RT (min) Delta RT
Lidocaine 1) 235.18 > 86.12) 235.18 > 58.1
97 1135
1.37 0.4
Tramadol 1) 264.2 > 58.12) 264.2 > 246.1
97 153
1.20 0.4
Amitriptyline 1) 278.2 > 1172) 278.2 > 105
112 1919
4.25 0.4
Biperidene 1)312.23 > 98.12) 312.23 > 55.1
123 1960
4.23 0.7
Oxazepam 1) 287.06 > 240.92) 287.06 > 268.9
112 197
3.99 0.4
Lorazepam 1) 321.02 > 274.92) 321.02 > 302.9
113 157
4.09 0.4
Chlorpromazine 1) 319.11 > 86.12) 319.11 > 58.1
112 1543
4.63 0.4
Diltiazem 1) 415.17 > 177.92) 415.17 > 149.9
128 1943
3.73 0.4
Naloxone 1) 328.16 > 3102) 328.16 > 212
123 1539
0.82 0.4
Nortriptyline (IS) 1) 264.18 > 2332) 264.18 > 91
97 719
4.17 0.4
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
7x10
0.125
0.150.175
0.2
0.2250.25
0.275
0.3
0.325
0.350.375
0.4
0.4250.45
0.475
0.5
0.525
0.550.575
0.6
0.6250.65
0.675
0.7
0.725
0.750.775
0.8
0.8250.85
0.875
0.9
0.925
0.950.975
1
1.025
1.05
1.075
1.11.125
1.15
1.1751.2
1.225
1.25
1.275
1.31.325
1.35
1.375
+ESI TIC Scan Frag=80.0V AOAC_BLANK_110228b.d
1 1
Counts vs. Acquisition Time (min)0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10
QuEChERS Extraction of Whole Blood MS Scan mass range 100-800, scan time 20 sec, Fragmentor 80 V, positive polarity. Injection volume 10 μL, 20% B to 75% B over 5.5 minutes. Hold 75% B for 2 minutes.
Poroshell 120 EC-C18, 2.7 μ, 2.1 x 100 mm, PN 695775-902Mobile Phase A: 5 mM Ammonium acetate, pH 5; 20:80 MeOH:WaterB: 5 mM Ammonium Acetate in ACNGT (ºC): 300 GF (l/min): 7Nebulizer (psi): 40SGT (ºC): 400SFG (l/min): 12Capillary (V): 3500NV (V): 500
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
3x10
0.1
0.2
0.3
0.40.50.6
0.7
0.80.9
1
1.1
1.21.3
1.4
1.51.6
1.71.8
1.9
2
2.12.2
2.3
2.4
2.5
2.62.72.8
2.93
3.1
3.2
3.3
3.43.5
3.6
3.73.8
3.94
4.1
4.2
4.34.4
4.5
4.6
4.74.84.9
5
5.1+ESI MRM Frag=112.0V [email protected] (278.2000 -> 117.0000) HQC_6.d
1 1
Counts vs. Acquisition Time (min)0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4 4.1 4.2 4.3 4.4 4.5 4.6
Nal
oxon
e
Lido
cain
e
Tram
adol
Oxa
zepa
mLo
raze
pam
Bipe
ride
n
Am
itri
ptyl
ine
Dilt
iaze
m
Chlo
rpro
maz
ine
Nor
trip
tylin
e (IS
)
LC/MS/MS Chromatograms of 100 ng/mL spiked whole blood sample after mini-QuEChERS extraction; AOAC (NaAc) and d-SPE (PSA)
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
3/23/2011
3x10
0.10.20.30.40.50.60.70.80.9
11.11.21.31.41.51.61.71.81.9
22.12.22.32.42.52.62.72.82.9
33.13.23.33.43.53.63.73.83.9
44.14.24.34.44.54.64.74.84.9
55.1
+ESI MRM Frag=112.0V [email protected] (278.2000 -> 117.0000) HQC_6.d
1 1
Counts vs. Acquisition Time (min)0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4 4.1 4.2 4.3 4.4 4.5 4.6
1x10
4.154.24.254.34.354.44.454.54.554.64.654.74.754.84.854.94.955
5.055.15.155.25.255.35.355.45.455.55.555.65.655.7
+ESI MRM Frag=112.0V [email protected] (287.1000 -> 240.9000) RE_L_1.d 1
Counts vs. Acquisition Time (min)3.053.13.153.23.253.33.353.43.453.53.553.63.653.73.753.83.853.93.9544.054.14.154.24.254.34.354.44.454.54.554.64.654.74.75
Signal-to-noise for Oxazepam and Lorazepam, at 10 ng/mL (10 ppb), SN = 3.0
For Research Use Only. Not for use in diagnostic procedures.
3/23/2011
Example of mini-QuEChERS extracted standard linear curve for Naloxone from 10-250 ng/mL (ppb), R2 = 0.991.
For Research Use Only. Not for use in diagnostic procedures.
Recovery and ReproducibilityCompound 25 ng/mL Spiked
Recovery RSD50 ng/mL Spiked
Recovery RSD100 ng/mL Spiked
Recovery RSD
Lidocaine 81.6 35.3 98.7 15.7 100 11.8
Tramadol 97.2 18.6 105 3.0 104 8.2
Amitriptyline 85 13.6 104 2.1 104 8.2
Biperidene 75.5 14.8 97 4.5 99 8.2
Oxazepam 60.4 17.3 77.0 9.2 78 8.6
Lorazepam 68.4 17.0 81.9 6.8 81.8 8.6
Chlorpromazine 75 14.1 110 10.3 105 6.3
Diltiazem 63.7 15.8 88.1 2.7 91.7 8.3
Naloxone 68 12.1 80.6 9.0 75.5 7.7
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.
Conclusion and Future Work• mini-QuEChERS approach for the extraction of pharmaceutical compounds
from whole blood offers an alternative to other sample preparation techniques
• mini-QuEChERS sample preparation is a simple, easy and cost effective approach, requiring minimal sample preparation expertise and equipment
• Extend the number and classifications evaluated
• Other biological matrices, postmortem blood• Future work will involve convenient form factors for both the mini-QuEChERS
extraction salts and d-SPE
3/23/2011
For Research Use Only. Not for use in diagnostic procedures.